The up-regulation of ANXA3 promoted the development of colorectal adenocarcinoma [49] and pancreatic carcinoma [50], and increases the metastatic risk of lung adenocarcinoma [51] and hepatic carcinoma [52]. Here, ANXA3 is linked to hepatocellular carcinoma.